Arsalan Habib is a Nephrology physician affiliated with University of Utah. OpenAlex indexes 12 publications with 509 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1250 E 3900 S Ste 410
St. Mark'S East Medical Building
Salt Lake City, UT 841241364
Telephone
801-281-5996Provider last certified this registry record 4 Aug 2023.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Travere Therapeutics, Inc.Program year20221 payment
- Travere Therapeutics, Inc.Program year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
67.6%Angiotensin receptor blocker (ARB)17.1%Losartan Potassium41%Valsartan39%Irbesartan21%Part D<11 patientsLoop diuretic13.2%Furosemide69%Bumetanide16%Torsemide16%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
22.6%Vitamin D3 Analog8%Calcitriol100%Part D≥23 patientsSGLT2 inhibitor6.9%Farxiga66%Jardiance34%Part D<11 patients+ 3 more classes in this area
Musculoskeletal
5.3%Xanthine oxidase inhibitor4.1%Allopurinol100%Part D≥17 patientsAlkaloid1.2%Colchicine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy
Canadian Journal of Kidney Health and Disease
2016 - Sedentary Behavior in Individuals With Diabetic Chronic Kidney Disease and Maintenance Hemodialysis
Journal of Renal Nutrition
2015 - The Association of Lipid-Modifying Medications With Mortality in Patients on Long-Term Peritoneal Dialysis
American Journal of Kidney Diseases
2007 - Role of Socioeconomic Status in Kidney Transplant Outcome
Clinical Journal of the American Society of Nephrology
2006
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Colman, MD
University of Utah
Michael Varner, MD
University of Utah
James Fang
University of Utah
Wallace Akerley, MD
University of Utah
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”